HER2-positive breast cancer is treated with the same broad tools as other breast cancers — surgery, radiation, and medicines that treat the whole body — plus something the other types do not have: medicines designed specifically to target the HER2 protein. Those HER2-targeted medicines are a central part of most plans for this type, usually given alongside chemotherapy. This guide explains, in general terms, how doctors build a treatment plan around that target.
Key Takeaways
- “HER2-positive” means the cancer cells carry extra copies of the HER2 protein, which encourages the cancer to grow — and gives treatment a clear target to aim at.
- HER2-targeted medicines are part of most treatment plans for this type, generally combined with chemotherapy, because the two work in different ways.
- Medicine treatment is often given before surgery, to shrink the cancer and reveal how well it responds; that response helps guide what happens afterwards.
- Surgery and radiation decisions follow the same principles as for other breast cancers, based on the size and extent of the cancer.
- Because some HER2-targeted medicines can affect the heart, heart checks before and during treatment are a routine part of planning. Every plan is individual — your care team will explain yours.
What “HER2-Positive” Means for Treatment
HER2 is a protein that sits on the surface of breast cells and helps control how they grow. In HER2-positive breast cancer, the cancer cells carry far more of this protein than normal — the result of extra copies of the HER2 gene — and that surplus drives the cells to grow and divide more readily. Laboratory testing on the biopsy sample establishes the result, as our guide to ER, PR, and HER2 testing explains, and our article on HER2-positive breast cancer covers the biology in plain language.
The same feature that makes this type tend to grow faster also gives it a vulnerability: medicines can be built to attach to the HER2 protein and interfere with it. That is why the treatment approach for HER2-positive cancer differs from, for example, the approach for triple-negative breast cancer, which has no such target. Our comparison of HER2-positive vs HER2-negative breast cancer sets the two side by side, and the overall framework doctors work within is described in our pillar guide on how breast cancer treatment plans are made.
The Information Doctors Use
Before recommending a plan, your team pulls together a standard set of facts:
| Factor | Why it matters |
|---|---|
| Stage (size and spread) | Whether the cancer is confined to the breast, involves lymph nodes, or has spread further — this sets the overall scale and order of treatment. |
| HER2 test result | Confirms the cancer is HER2-positive, which is what makes HER2-targeted medicines part of the plan. |
| Hormone receptor results | Some HER2-positive cancers also carry hormone receptors; if so, hormone therapy usually joins the plan as well. |
| Lymph node involvement | Influences surgery, radiation, and how much whole-body treatment is advised. |
| Heart health | Some HER2-targeted medicines can affect heart function, so the heart is checked before treatment starts and monitored during it. |
| Your health and preferences | Other medical conditions, medicines you take, and what matters to you all shape the final plan. |
HER2-Targeted Medicines: The Centerpiece
HER2-targeted medicines are designed to find the HER2 protein on cancer cells and block its growth signals. Several kinds exist — most are antibody-based medicines, built to attach precisely to HER2 — and they are usually given in a treatment center by infusion into a vein, though some are given by injection. Our explainer on targeted therapy for HER2-positive breast cancer describes how these medicines work in more detail.
Two features of how they are used are worth knowing in general terms. First, they are generally combined with chemotherapy rather than given entirely on their own, because the medicines attack the cancer in complementary ways and the combination is more effective than either alone in most situations. Second, targeted treatment commonly continues beyond surgery for a period, even when the visible cancer has been removed — the aim is to deal with any cancer cells that might remain elsewhere in the body. Which medicines, in what combination, and for how long is decided by your team for your stage and situation; there is no single standard plan that fits everyone with this type.
Chemotherapy and the Order of Treatment
Chemotherapy medicines circulate through the whole body and attack dividing cells. For HER2-positive breast cancer, chemotherapy alongside HER2-targeted medicines is a core part of treatment for most people whose cancer has grown beyond the very earliest, smallest stage — and the exact recommendation is always matched to the individual case. Our guide to chemotherapy for breast cancer and what to expect describes how treatment days and cycles generally work.
One pattern is especially common in this type: treatment given before surgery, called neoadjuvant treatment. Doctors often favour this order for two reasons. First, shrinking the cancer first can make surgery easier and sometimes makes breast-conserving surgery possible. Second, it provides information: when the removed tissue is examined afterwards, the team can see how well the cancer responded to the medicines. A complete response — no active cancer found in the removed tissue — is a favourable sign, while cancer that remains may lead the team to adjust the treatment that follows surgery. Our article on treatment before surgery explains this sequencing in more detail. Very small, early HER2-positive cancers are the main exception to the pattern: some are treated with surgery first and a lighter medicine plan afterwards, decided case by case.
Surgery and Radiation Decisions
Surgery removes the cancer itself and takes one of two forms: breast-conserving surgery (lumpectomy), which removes the cancer with a rim of healthy tissue, or mastectomy, which removes the whole breast. The choice depends on the size and position of the cancer, how it responded to any treatment given first, and your own preferences after a full discussion. Being HER2-positive does not by itself require mastectomy; the same principles apply as for other types. Lymph nodes under the arm are usually sampled during the operation to check for spread, and reconstruction can be discussed with the surgical team if mastectomy is chosen.
Radiation is commonly recommended after breast-conserving surgery, to lower the chance of the cancer returning in that breast. After mastectomy, whether it is advised depends on features such as the size of the cancer and whether lymph nodes were involved. Your team will explain whether radiation fits your situation and what a course of it involves day to day.
If the Cancer Is Also Hormone-Receptor Positive
HER2 status is only one of the test results on a pathology report. Some HER2-positive cancers also carry estrogen or progesterone receptors — sometimes called “triple-positive” when all three are present. When that is the case, hormone therapy (medicines that block hormones or lower their levels) usually becomes part of the plan as well, generally alongside or following the chemotherapy and targeted treatment, often continuing for a longer period after the main treatment ends. Our guide to hormone therapy for breast cancer explains how those medicines work. If your cancer is hormone-receptor negative, hormone therapy has nothing to act on and is not part of the plan — your team will make clear which situation is yours.
Heart Monitoring and Side Effects
One practical feature of HER2-targeted treatment deserves a mention, because it often surprises people: some of these medicines can affect how well the heart pumps. For that reason, your heart function is typically checked before treatment begins and at intervals during it, using a painless scan. If the checks suggest the heart is under strain, the team may pause or adjust treatment. Tell your team promptly about new breathlessness, swelling in the ankles, or unusual tiredness — most people complete treatment without heart problems, but the monitoring exists so any issue is caught early.
Other side effects depend on the particular medicines in your plan and overlap with chemotherapy effects — tiredness, changes in blood counts, and digestive upsets are common themes. Our overview of managing chemotherapy side effects covers the general principle: report side effects early, because most are easier to settle when they are small.
Questions to Ask Your Doctor
- What is the stage of my cancer, and has it reached any lymph nodes?
- Which HER2-targeted medicines are planned for me, and how are they given?
- Will treatment come before or after surgery in my case — and why that order?
- Is my cancer also hormone-receptor positive, and if so, how does that change the plan?
- How will my heart be checked before and during treatment?
- How will you judge how well the treatment is working?
- What follow-up schedule do you recommend once treatment ends?
Frequently Asked Questions
If there is a targeted medicine, why do I also need chemotherapy?
Because the two attack the cancer differently, and for this type they generally work better together than either would alone. The targeted medicines home in on the HER2 protein; chemotherapy attacks dividing cells throughout the body. In most situations beyond the very earliest stage, doctors recommend the combination — your oncologist will explain the reasoning for your case.
Does HER2-positive mean a worse outlook?
This type tends to grow faster than HER2-negative cancers, and before targeted medicines existed that did mean a poorer outlook. HER2-targeted treatment has changed that picture substantially. Outlook today depends mainly on the stage, how the cancer responds to treatment, and the individual — many people respond very well. Your care team can talk about your own situation far better than general labels can.
How are HER2-targeted medicines given, and for how long?
Most are given in a treatment center, usually by infusion into a vein, on a repeating cycle alongside or after chemotherapy; some newer ones are given by injection. Treatment commonly continues for a period after surgery as well. The exact medicines and total length vary with your stage and how the cancer responds, so this is a good question to put to your own team.
Why does my heart need checking for a breast cancer treatment?
Some HER2-targeted medicines can weaken the heart’s pumping in a minority of people. The effect is usually picked up on monitoring scans before it causes symptoms, and it often improves when treatment is paused or adjusted. The checks are painless and routine — they are a safety net, not a sign that a problem is expected.
Can HER2 status be wrong, or change?
Testing is standardised and reliable, and borderline results are checked with a second type of test before the status is settled. Occasionally, if a cancer returns, the team may test again, because results can rarely differ between the original cancer and a recurrence. If you are ever unsure what your result was, ask — it is a central fact in your record.
Related Articles
- How Breast Cancer Treatment Plans Are Made: A Plain-Language Guide
- HER2-Positive Breast Cancer Explained
- Targeted Therapy for HER2-Positive Breast Cancer
- HER2-Positive vs HER2-Negative Breast Cancer: What the Difference Means
- Triple-Negative vs HER2-Positive Breast Cancer: How They Differ
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.